In this task, you need to Translate Czech text to English.

[Q]: Skl °sk  vanov  tavic  pec pro kontinu ln  p° pravu skloviny s dielektrick²m oh°evem skl °sk ho kmene, vs dky  i st°ep  pomoc  vysokofrekven n ho mikrovlnn ho z °en  se skl d  ze skeletu pece /8/, ve kter m je ulo ena tavic  vana /1/, jej   dno je na spodn  vn jÜ  stran  opat°eno kompaktn  absorp n  deskou /2/ z materi lu, absorbuj c ho mikrovlnn  z °en , odol vaj c ho teplot m do 1600 .degree.C, jeho  ztr tov² ·hel tg.delta. je v rozmez  teplot 20 .degree.C a  1600 .degree.C minim ln  prom nn² a m  ·tlum elektromagnetick ho z °en  v p°  n m sm ru menÜ  ne  3 dB, p°i em  Ü °ka tavic  vany /1/ je menÜ  nebo nejv²Üe rovna dvojn sobku vniku elektromagnetick  vlny na dan m kmito tu a zdroje /4/ elektromagnetick ho z °en  jsou um st ny uvnit° skeletu pece /8/ t sn  u pod ln²ch bo n ch st n vn  tavic  vany /1/.\
[A]: The glass melting furnace for the continual preparation of molten glass with dielectric heating of the glass batch, charge or glass splinters by means of high frequency microwave radiation, is composed of a furnace skeleton (8), with the melting furnace (1) fitted inside, whose bottom is equipped on the lower outer side with a compact absorption plate (2) from a material absorbing microwave radiation, resistant to temperatures up to 1600 degrees C, whose loss angle tgδ is minimally variable between 20 degrees C and 1600 degrees C and has an electromagnetic radiation attenuation at a bias of less than 3 dB. The width of the melting furnace (1) is less or at most equal to a doubling of the penetration of electromagnetic waves at the given frequency and the sources (4) of electromagnetic radiation are located inside the furnace skeleton (8), close to the longitudinal side wall of the outside of the melting furnace (1).<IMAGE>


[Q]: Zpusob výroby syntetických sklenených vláken s obsahem nejméne 14 % hliníku, mereno podle hmotnosti Al.sub.2.n.O.sub.3.n., vztaženo na oxidy, skládající se z vytvorení samonosného sloupce minerální nakládky v šachtové peci alespon cástecne z briket, z roztavení nakládky za vzniku taveniny na dne pece, která má stejné složení jako vlákna, dále z odstranení taveniny ze dna pece a z jejího zvláknení. Nejméne jedna ctvrtina hliníku v nakládce je vložena jako cásticové minerály s obsahem aluminy do briket, a tyto minerály obsahují 0,5 až 10 % hmotn. kovového hliníku, 50 až 90 % hmotn. aluminy Al.sub.2.n.O.sub.3.n. a 0 až 49,5 % hmotn. ostatních materiálu.
[A]: The present invention relates to a process of producing man-made glass fibers having a composition which contains at least 14 percent aluminium measured as weight Ali2Oi3 based on oxides, comprising providing in a shaft furnace a self-supporting stack of mineral charge which includes at least partially briquettes, melting the charge to provide a melt at the base of the furnace having the composition of the fibers, removing the melt from the base of the furnace and spinning the melt, characterised in that at least one quarter of the aluminium in the charge is introduced as particulate alumina-containing mineral in briquettes and the particulate alumina-containing mineral contains from 0.5 to 10 percent by weight of metallic aluminium, 50 to 90 percent by weight of alumina Ali2Oi3 and 0 to 49.5 percent by weight of other materials.


[Q]: Předmětem řešení je způsob stabilizace farmaceutické kompozice ve formě tablety vhodných pro orální podávání obsahující Valsartan vzorce I, chemicky (S)-3-methyl-2-(N{[2´-(2H-1,2,3,4-tetrazol-5-yl)bifenyl-4­­yl]methyl}pentanamido)butanová kyselina, nebo jeho farmaceuticky akceptovatelné soli v kombinaci se Sacubitrilem vzorce II, chemicky ethylester (2R,4S)-5-(bifenyl-4-yl)-4-[(3-karboxypropionyl)amino]-2-methylpentanové kyseliny, nebo jeho farmaceuticky akceptovatelnými solemi, přičemž kompozice je uložena ve farmaceutickém obalu, v němž je udržována inertní atmosféra pomocí dusíku.
[A]:
The object of the invention is a method of stabilizing a pharmaceutical composition in the form of a tablet suitable for oral administration comprising Valsartan of formula I, chemically (S) -3-methyl-2- (N {[2'- (2H-1,2,3,4-tetrazol- 5-yl) biphenyl-4-yl] methyl} pentanamido) butanoic acid, or a pharmaceutically acceptable salt thereof, in combination with a Sacubitrile of formula II, (2R, 4S) -5- (biphenyl-4-yl) -4 - [- 3-carboxypropionyl) amino] -2-methylpentanoic acid, or a pharmaceutically acceptable salt thereof, wherein the composition is contained in a pharmaceutical container in which an inert atmosphere is maintained with nitrogen.